Loading...
CRON logo

Cronos Group Inc.TSX:CRON Stock Report

Market Cap CA$1.4b
Share Price
CA$3.52
n/a
1Y23.1%
7D-4.1%
Portfolio Value
​
View

Cronos Group Inc.

TSX:CRON Stock Report

Market Cap: CA$1.4b

Cronos Group (CRON) Stock Overview

A cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. More details

CRON fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 72.3% below our estimate of its fair value

Earnings are forecast to grow 50.71% per year

Risk Analysis

No risks detected for CRON from our risk checks.

CRON Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

CRON logo
Cronos Group

Regulatory Shifts In Israel And Germany Will Hinder Cannabis Growth

Key Takeaways Reliance on international markets and regulatory uncertainty could threaten revenue growth and add financial volatility as legal or reimbursement environments shift. Intensifying price competition, ESG scrutiny, and rising operational costs may erode margin improvements and create challenges for sustained profitability.
View narrative
CA$3.19
FV
10.3% overvalued intrinsic discount
5.48%
Revenue growth p.a.
24
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CRON logo
Cronos Group

GrowCo Capacity And Global Markets Will Unlock Potential

Key Takeaways Expanded cultivation capacity and international market access are expected to drive revenue growth and increased market diversification. Strong brand performance and a shift to higher-margin products support improved profitability and margin expansion.
View narrative
CA$4.24
FV
16.9% undervalued intrinsic discount
14.57%
Revenue growth p.a.
115
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
CRON logo
Cronos Group

Global Cannabis Legalization Will Expand Wellness And Medicine Markets

Key Takeaways Strong premium brand portfolio, international expansion, and R&D investments position Cronos for sustainable margin growth and increased global market share as cannabis normalization accelerates. Robust financial health and strategic partnerships set Cronos up as a leading consolidator with significant upside from licensing, M&A, and new revenue streams.
View narrative
CA$5
FV
29.6% undervalued intrinsic discount
6.58%
Revenue growth p.a.
9
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
View Stock Community
UNCY logo
Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

View narrative
4k
users have viewed this narrative
13users have liked this narrative
0users have commented on this narrative
73users have followed this narrative
US$21.53
68.3% undervalued intrinsic discount
stuart_roberts's Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

Cronos Group Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cronos Group
Historical stock prices
Current Share PriceCA$3.52
52 Week HighCA$4.66
52 Week LowCA$2.27
Beta1.24
1 Month Change-0.28%
3 Month Change1.73%
1 Year Change23.08%
3 Year Change31.34%
5 Year Change-73.15%
Change since IPO324.10%

Recent News & Updates

Recent updates

Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Dec 13
Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up

Aug 15
Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up
User avatar

GrowCo Expansion Will Boost Operations But Strain Cash Flow

Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.

We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow

May 31
We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow

Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce

Apr 01
Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce

We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth

Mar 02
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth

Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)

Feb 02
Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)

Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth

Nov 09
Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth

We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely

Jul 17
We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely

Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors

Jun 20
Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors

We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth

Feb 09
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth

A Look At The Intrinsic Value Of Cronos Group Inc. (TSE:CRON)

Oct 12
A Look At The Intrinsic Value Of Cronos Group Inc. (TSE:CRON)

Shareholder Returns

CRONCA PharmaceuticalsCA Market
7D-4.1%-3.1%-0.9%
1Y23.1%17.6%36.0%

Return vs Industry: CRON exceeded the Canadian Pharmaceuticals industry which returned 17.6% over the past year.

Return vs Market: CRON underperformed the Canadian Market which returned 36% over the past year.

Price Volatility

Is CRON's price volatile compared to industry and market?
CRON volatility
CRON Average Weekly Movement7.1%
Pharmaceuticals Industry Average Movement13.9%
Market Average Movement10.6%
10% most volatile stocks in CA Market19.7%
10% least volatile stocks in CA Market3.6%

Stable Share Price: CRON has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: CRON's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a610Mike Gorensteinthecronosgroup.com

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.

Cronos Group Inc. Fundamentals Summary

How do Cronos Group's earnings and revenue compare to its market cap?
CRON fundamental statistics
Market capCA$1.36b
Earnings (TTM)-CA$12.91m
Revenue (TTM)CA$200.38m
6.7x
P/S Ratio
-103.3x
P/E Ratio

Is CRON overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRON income statement (TTM)
RevenueUS$146.59m
Cost of RevenueUS$88.19m
Gross ProfitUS$58.40m
Other ExpensesUS$67.85m
Earnings-US$9.45m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.025
Gross Margin39.84%
Net Profit Margin-6.44%
Debt/Equity Ratio0%

How did CRON perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/05 01:29
End of Day Share Price 2026/03/05 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cronos Group Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jesse PytlakATB Cormark Historical (Cormark Securities)
Vahan AjamianBeacon Securities Limited
Nadine SarwatBernstein